Search research articles
Contact Us
Filters
Showing results (111-120 of 937) with videos related to
Page
of 94
Sort By:
STAR Protocols
|
November 5, 2023
Protocol for the expansion of mouse immune effector cells for in vitro and in vivo studies
Thomas Look, Hanna Meister, Michael Weller, et al.
Expert Opinion on Pharmacotherapy
|
April 8, 2016
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives
Katharina Seystahl, Dorothee Gramatzki, Patrick Roth, et al.
Neuro-Oncology
|
October 31, 2015
Immunosuppressive mechanisms in glioblastoma
Edjah K Nduom, Michael Weller, Amy B Heimberger
Expert Review of Anticancer Therapy
|
October 25, 2013
Tumor-associated edema in brain cancer patients: pathogenesis and management
Patrick Roth, Luca Regli, Michaela Tonder, et al.
Current Opinion in Neurology
|
October 25, 2013
Malignant astrocytoma in elderly patients: where do we stand?
Ghazaleh Tabatabai, Roger Stupp, Wolfgang Wick, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
June 28, 2007
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand
Johannes Rieger, Brigitte Frank, Michael Weller, et al.
Neuro-Oncology Advances
|
October 10, 2022
Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo
Evelina Blomberg, Manuela Silginer, Patrick Roth, et al.
Nature Medicine
|
July 9, 2009
Will integrin inhibitors have proangiogenic effects in the clinic?
Michael Weller, David Reardon, Burt Nabors, et al.
Nature Reviews. Clinical Oncology
|
April 13, 2018
Current state of immunotherapy for glioblastoma
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, et al.
Expert Review of Anticancer Therapy
|
May 19, 2012
Pathogenesis and management of primary CNS lymphoma
Patrick Roth, Agnieszka Korfel, Peter Martus, et al.
Page
of 94
Search research articles
Search
Showing results (111-120 of 937) with videos related to
Sort By:
Page
of 94
STAR Protocols
|
November 5, 2023
Protocol for the expansion of mouse immune effector cells for in vitro and in vivo studies
Thomas Look, Hanna Meister, Michael Weller, et al.
Expert Opinion on Pharmacotherapy
|
April 8, 2016
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives
Katharina Seystahl, Dorothee Gramatzki, Patrick Roth, et al.
Neuro-Oncology
|
October 31, 2015
Immunosuppressive mechanisms in glioblastoma
Edjah K Nduom, Michael Weller, Amy B Heimberger
Expert Review of Anticancer Therapy
|
October 25, 2013
Tumor-associated edema in brain cancer patients: pathogenesis and management
Patrick Roth, Luca Regli, Michaela Tonder, et al.
Current Opinion in Neurology
|
October 25, 2013
Malignant astrocytoma in elderly patients: where do we stand?
Ghazaleh Tabatabai, Roger Stupp, Wolfgang Wick, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
June 28, 2007
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand
Johannes Rieger, Brigitte Frank, Michael Weller, et al.
Neuro-Oncology Advances
|
October 10, 2022
Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo
Evelina Blomberg, Manuela Silginer, Patrick Roth, et al.
Nature Medicine
|
July 9, 2009
Will integrin inhibitors have proangiogenic effects in the clinic?
Michael Weller, David Reardon, Burt Nabors, et al.
Nature Reviews. Clinical Oncology
|
April 13, 2018
Current state of immunotherapy for glioblastoma
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, et al.
Expert Review of Anticancer Therapy
|
May 19, 2012
Pathogenesis and management of primary CNS lymphoma
Patrick Roth, Agnieszka Korfel, Peter Martus, et al.
Page
of 94